Moderator:
Diane E. Hadley, Pharm.D., PGY2 Ambulatory Care Pharmacy Resident
Panelists:
Seena L. Haines, Pharm.D., BCACP
Philip T. Rodgers, Pharm.D., BCPS
Citation:
Gadde KM et. al. Effects of low-dose, controlled release, phenterminea plus topiramate combination on weight and associated comorbidities in overweight and obese adults: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
The CONQUER study was double-blind, placebo-controlled clinical trial that examined the potential benefits of the combination product Qsymia (phenterimine and topiramate) in patients who were overweight and obese. Our moderator and panelists explore the findings of this study and how this new information should be applied to practice.
Tell us what you think? Given safety concerns that have resulted in restrictions in its prescribing and dispensing, when should phentermine plus topiramate be considered for weight loss?
Loading ...
iForumRx.org is a web-based community of practice designed to inform ambulatory care pharmacy specialists, pharmacy residents, and student pharmacists about high-quality, practice-changing evidence.